The United Kingdom and the United States have announced a significant commercial pact that will preserve zero duties on UK medicine exports entering the American market.
The Terms of the Pact
As part of the deal, the UK has committed to increase funding on drugs through the National Health Service (NHS). This pledge secures that duties on these key products will be held at zero for a duration of the next three years.
This development is in response to recent threats to hike tariffs on branded drug products, with potential rates mentioned reaching 100%.
"This agreement with the UK strengthens the worldwide climate for innovative medicines and brings much-needed equity to U.S.–U.K. pharmaceutical trade," a statement said.
Economic Impact
Medicines are one of the Britain's biggest export categories to the US, which is by far the primary buyer for leading British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure made up nearly one-fifth of total UK exports in that period.
"This agreement protects work, increases funding and sets the stage for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement includes several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at 15%. In the past, repayments topped 20%.
Recent Tensions
The pact follows a ongoing row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
This friction were intensified by claims that US consumers were charged a premium for the same drugs than people in the UK and Europe.
Recently, several large drug company projects in the UK have been delayed or cancelled, while major expansions have been announced toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
